Topical dobesilate eye drops for ophthalmic primary pterygium

Uloženo v:

Podrobná bibliografie
Vydáno v:	BMJ Case Reports vol. 2012 (Sep 2025), p. bcr1220115449
Hlavní autor:	Cuevas, Pedro
Další autoři:	Outeiriño, Luis A, Angulo, Javier, Giménez-Gallego, Guillermo
Vydáno:	BMJ Publishing Group LTD
Témata:	Diabetes Vascular endothelial growth factor Neutrophils Fibroblasts Stem cells Cornea Angiogenesis Cytokines
On-line přístup:	Citation/Abstract Full Text + Graphics Full Text - PDF
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Abstrakt:	Selective inhibition of fibroblast growth factor and vascular endothelial growth factor signalling pathways is effective in causing regression of pterygia. Prompt regression of fibrovascular mass and conjunctival angiogenesis was documented 2 weeks after topical administration of dobesilate eye drops twice daily. At 3-month follow-up, no recurrence was seen and no ocular irritation and burning were noted. The authors believe that this is the first known successful use of topical dobesilate in primary pterygium.
ISSN:	1757-790X
DOI:	10.1136/bcr.12.2011.5449
Zdroj:	Health & Medical Collection